Patients with symptomatic nOH due to Parkinson disease , multiple system atrophy , pure autonomic failure , or nondiabetic autonomic neuropathy underwent open-label droxidopa dose optimization ( @-@ mg @ times daily ) , followed , in responders , by @-day washout and then a @-day double-blind trial of droxidopa vs placebo .